Partnership PotentialBrilaroxazine is an attractive partnering candidate due to its promising data in treating schizophrenia.
Safety ProfileThe long-term safety profile of Brilaroxazine remained positive, with a 35% discontinuation rate that compares favorably to the 60%-70% typically seen in similar-duration trials of other antipsychotics.
Therapeutic PotentialBrilaroxazine demonstrated sustained, dose-dependent efficacy across all key symptom domains, underscoring its therapeutic potential in treating schizophrenia.